SUPPLEMENTAL DATA

Figure S1. Time of Onset of the Most Common (≥10%) TEAEs During OLE Treatment



OLE = open-label extension; TEAEs = treatment-emergent adverse events.

Table S1. Duration of Exposure (Safety Population)

	All cenobamate (n=355)	**Cenobamate/cenobamate (n=265)**	**Placebo/cenobamate (n=90)**
≤3 months	4 (1.1)	0 (0.0)	4 (4.4)
≥6 months	336 (94.6)	256 (96.6)	80 (88.9)
12 months	294 (82.8)	221 (83.4)	73 (81.1)
18 months	263 (74.1)	196 (74.0)	67 (74.4)
24 months	244 (68.7)	181 (68.3)	63 (70.0)
36 months	224 (63.1)	168 (63.4)	56 (62.2)
48 months	213 (60.0)	161 (60.8)	52 (57.8)

Values are given as n (%).

Table S2. Serious TEAEs by System Organ Class and MedDRA Preferred Term

MedDRA System Organ Class (SOC) Preferred Term (PT), n (%)	**All cenobamate (n=355)**	**Cenobamate/ cenobamate (n=265)**	**Placebo/ cenobamate (n=90)**
Subjects with at least one serious TEAE	72 (20.3)	55 (20.8)	17 (18.9)
Blood and lymphatic system disorders	2 (0.6)	2 (0.8)	0
Anaemia	1 (0.3)	1 (0.4)	0
Anaemia macrocytic	1 (0.3)	1 (0.4)	0
Cardiac disorders	5 (1.4)	1 (0.4)	4 (4.4)
Myocardial infarction	2 (0.6)	0	2 (2.2)
Bundle branch block left	1 (0.3)	1 (0.4)	0
Cardiac arrest	1 (0.3)	0	1 (1.1)
Cardiogenic shock	1 (0.3)	0	1 (1.1)
Pericarditis	1 (0.3)	1 (0.4)	0
Ear and labyrinth disorders	4 (1.1)	1 (0.4)	3 (3.3)
Vertigo	4 (1.1)	1 (0.4)	3 (3.3)
Eye disorders	2 (0.6)	1 (0.4)	1 (1.1)
Diplopia	1 (0.3)	1 (0.4)	0
Vision blurred	1 (0.3)	0	1 (1.1)
Gastrointestinal disorders	5 (1.4)	5 (1.9)	0
Enterocolitis	1 (0.3)	1 (0.4)	0
Gastrointestinal ischaemia	1 (0.3)	1 (0.4)	0
Mesenteric vein thrombosis	1 (0.3)	1 (0.4)	0
Subileus	1 (0.3)	1 (0.4)	0
Vomiting	1 (0.3)	1 (0.4)	0
General disorders and administration site conditions	2 (0.6)	2 (0.8)	0
Medical device site reaction	1 (0.3)	1 (0.4)	0
Sudden unexplained death in epilepsy	1 (0.3)	1 (0.4)	0
Hepatobiliary disorders	5 (1.4)	5 (1.9)	0
Cholelithiasis	2 (0.6)	2 (0.8)	0
Biliary dyskinesia	1 (0.3)	1 (0.4)	0
Cholangitis acute	1 (0.3)	1 (0.4)	0
Cholecystitis	1 (0.3)	1 (0.4)	0
Cholecystitis acute	1 (0.3)	1 (0.4)	0
Infections and infestations	9 (2.5)	8 (3.0)	1 (1.1)
Pneumonia	2 (0.6)	2 (0.8)	0

MedDRA System Organ Class (SOC) Preferred Term (PT), n (%)	**All cenobamate (n=355)**	**Cenobamate/ cenobamate (n=265)**	**Placebo/ cenobamate (n=90)**
Pyelonephritis	2 (0.6)	1 (0.4)	1 (1.1)
Sepsis	2 (0.6)	2 (0.8)	0
Appendicitis	1 (0.3)	1 (0.4)	0
Appendicitis perforated	1 (0.3)	1 (0.4)	0
Enterocolitis bacterial	1 (0.3)	1 (0.4)	0
Retroperitoneal abscess	1 (0.3)	1 (0.4)	0
Urinary tract infection	1 (0.3)	1 (0.4)	0
Injury, poisoning and procedural complications	19 (5.4)	17 (6.4)	2 (2.2)
Accidental overdose	2 (0.6)	2 (0.8)	0
Clavicle fracture	2 (0.6)	2 (0.8)	0
Concussion	2 (0.6)	1 (0.4)	1 (1.1)
Brain contusion	1 (0.3)	1 (0.4)	0
Contusion	1 (0.3)	1 (0.4)	0
Craniocerebral injury	1 (0.3)	1 (0.4)	0
Foot fracture	1 (0.3)	1 (0.4)	0
Hand fracture	1 (0.3)	1 (0.4)	0
Head injury	1 (0.3)	1 (0.4)	0
Humerus fracture	1 (0.3)	0	1 (1.1)
Joint dislocation	1 (0.3)	1 (0.4)	0
Ligament injury	1 (0.3)	1 (0.4)	0
Muscle rupture	1 (0.3)	0	1 (1.1)
Post procedural haemorrhage	1 (0.3)	1 (0.4)	0
Radius fracture	1 (0.3)	0	1 (1.1)
Road traffic accident	1 (0.3)	1 (0.4)	0
Spinal compression fracture	1 (0.3)	1 (0.4)	0
Splenic rupture	1 (0.3)	1 (0.4)	0
Tendon injury	1 (0.3)	1 (0.4)	0
Tibia fracture	1 (0.3)	0	1 (1.1)
Toxicity to various agents	1 (0.3)	1 (0.4)	0
Wound dehiscence	1 (0.3)	1 (0.4)	0
Metabolism and nutrition disorders	1 (0.3)	1 (0.4)	0
Hyponatraemia	1 (0.3)	1 (0.4)	0
Musculoskeletal and connective tissue disorders	1 (0.3)	0	1 (1.1)

MedDRA System Organ Class (SOC) Preferred Term (PT), n (%)	**All cenobamate (n=355)**	**Cenobamate/ cenobamate (n=265)**	**Placebo/ cenobamate (n=90)**
Soft tissue disorder	1 (0.3)	0	1 (1.1)
Neoplasms benign, malignant, and unspecified (including cysts and polyps)	7 (2.0)	5 (1.9)	2 (2.2)
Bladder neoplasm	1 (0.3)	1 (0.4)	0
Breast cancer	1 (0.3)	1 (0.4)	0
Colon adenoma	1 (0.3)	1 (0.4)	0
Colorectal cancer	1 (0.3)	1 (0.4)	0
Invasive ductal breast carcinoma	1 (0.3)	1 (0.4)	0
Leiomyoma	1 (0.3)	0	1 (1.1)
Renal cell carcinoma	1 (0.3)	0	1 (1.1)
Nervous system disorders	20 (5.6)	12 (4.5)	8 (8.9)
Seizure	5 (1.4)	4 (1.5)	1 (1.1)
Seizure cluster	3 (0.8)	2 (0.8)	1 (1.1)
Dizziness	2 (0.6)	2 (0.8)	0
Epilepsy	2 (0.6)	2 (0.8)	0
Generalised tonic-clonic seizure	2 (0.6)	1 (0.4)	1 (1.1)
Balance disorder	1 (0.3)	1 (0.4)	0
Cerebellar haematoma	1 (0.3)	0	1 (1.1)
Cerebral infarction	1 (0.3)	0	1 (1.1)
Cerebrovascular accident	1 (0.3)	0	1 (1.1)
Dysarthria	1 (0.3)	0	1 (1.1)
Intracranial hypotension	1 (0.3)	0	1 (1.1)
Paraesthesia	1 (0.3)	1 (0.4)	0
Partial seizures with secondary generalisation	1 (0.3)	1 (0.4)	0
Postictal headache	1 (0.3)	1 (0.4)	0
Sinus headache	1 (0.3)	0	1 (1.1)
Psychiatric disorders	4 (1.1)	4 (1.5)	0
Completed suicide	1 (0.3)	1 (0.4)	0
Psychogenic seizure	1 (0.3)	1 (0.4)	0
Psychomotor retardation	1 (0.3)	1 (0.4)	0
Psychotic disorder	1 (0.3)	1 (0.4)	0
Renal and urinary disorders	1 (0.3)	1 (0.4)	0
Hydronephrosis	1 (0.3)	1 (0.4)	0

MedDRA System Organ Class (SOC) Preferred Term (PT), n (%)	**All cenobamate (n=355)**	**Cenobamate/ cenobamate (n=265)**	**Placebo/ cenobamate (n=90)**
Reproductive system and breast disorders	3 (0.8)	3 (1.1)	0
Benign prostatic hyperplasia	1 (0.3)	1 (0.4)	0
Metrorrhagia	1 (0.3)	1 (0.4)	0
Ovarian cyst	1 (0.3)	1 (0.4)	0
Uterine polyp	1 (0.3)	1 (0.4)	0
Respiratory, thoracic, and mediastinal disorders	2 (0.6)	2 (0.8)	0
Pulmonary embolism	1 (0.3)	1 (0.4)	0
Respiratory disorder	1 (0.3)	1 (0.4)	0
Vascular disorders	1 (0.3)	1 (0.4)	0
Deep vein thrombosis	1 (0.3)	1 (0.4)	0

Classification of a serious TEAE included any AE that was fatal, life-threatening, or required or prolonged hospital stay; or resulted in persistent or significant disability or incapacity, congenital anomaly or birth defect, or an important medical event. Patients with multiple events within a SOC or multiple events within a PT are reported only once within the respective SOC/PT. TEAEs are defined as AEs with onset after the start of study medication, up to last dose date of study medication + 30 days (or analysis cut-off date whichever comes first), or onset before study medication and worsened after starting study medication, up to last dose date of study medication + 30 days (or analysis cut-off date whichever comes first).

AE = adverse event; SAE = serious adverse event; TEAE = treatment-emergent adverse event.